Lexicon Pharmaceuticals just saw its price target nudged higher by $0.20, a move that reflects updated assumptions rather than a wholesale rethink of the story. Analysts describe this change as the ...

Lexicon Pharmaceuticals won't take no for an answer. The Texas pharma—convinced of the value of its diabetes candidate sotagliflozin—has clapped back at its latest rejection from the FDA, asking to be ...

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Lexicon Pharmaceuticals will lay off 60% of its ...

“It's a wonderful morning for Lexicon, our scientists, clinicians and the patients and principal investigators,” summed up CEO and Director Lonnel Coats, as the biotech reported results from a phase 2 ...

Despite winning an FDA approval in 2023 and gaining clarity in May on the regulatory path forward for its Type 1 diabetes prospect sotagliflozin, Lexicon Pharmaceuticals hasn’t had an easy go of it in ...

Detailed price information for Lexicon Pharmaceutcl (LXRX-Q) from The Globe and Mail including charting and trades.

Lexicon Pharmaceuticals (LXRX) has priced its public offering of 32M shares of its common stock, par value $0.001, at $1.30 per share to raise $41.6M. The firm has granted the underwriters a 30-day ...

Lexicon Pharmaceuticals received FDA approval to market its heart failure drug Inpefa, as well as a broad label compared to rivals like AstraZeneca's Farxiga and Lilly's Jardiance. The company faces ...

Lexicon Pharmaceuticals announced that it will present data on diabetic peripheral neuropathic pain (DPNP) at the 7th Annual Meeting of the American Society of Pain and Neuroscience (ASPN 2025) in ...